Last updated: February 26, 2026
What is the Current Market for EVISTA?
EVISTA (raloxifene hydrochloride), marketed by Eli Lilly and Company, is a selective estrogen receptor modulator (SERM) approved for reducing the risk of invasive breast cancer in postmenopausal women and treating osteoporosis. It generated approximately $300 million in global sales in 2022, with the U.S. accounting for nearly 90%.
The drug competes with other osteoporosis drugs like bisphosphonates (e.g., alendronate) and newer agents such as romosozumab. Its niche focus on breast cancer risk reduction differentiates it from broader osteoporosis therapies, but limits its penetration outside this indication.
How is the Market Expected to Evolve?
The global osteoporosis market was valued at $12.1 billion in 2022 and is projected to reach $17.4 billion by 2030, growing at a T CAGR of 4.7%. The breast cancer prevention segment, although smaller, shows consistent demand driven by screening campaigns and postmenopausal care guidelines.
Increased awareness of osteoporosis and breast cancer risk in aging populations supports continued demand. The expansion of indications, such as potential use of raloxifene for other estrogen-related conditions, remains under investigation but is unlikely to significantly alter its primary use.
Market Drivers and Challenges
Main drivers include aging populations and increasing awareness of breast cancer risk factors. Legislative initiatives encouraging osteoporosis screening influence prescription volume.
Challenges include generic erosion. The patent for EVISTA expired in 2021, leading to the entry of generic raloxifene products in 2022. These generics are priced 55%-60% lower than branded EVISTA, exerting downward pressure on revenues.
Price Trends and Projections
Historical Pricing
- Brand EVISTA (2021): Average wholesale price (AWP) for a 60 mg tablet was approximately $10.
- 2018-2021: Prices remained stable, with minor fluctuations due to inflation and supply chain factors.
Effects of Patent Expiry and Generics
Post-2021 patent expiration led to generic versions retailing at $4-$5 per tablet, a reduction of 50%. The branded price decline corresponded with increased generic market share, which exceeded 65% in 2022.
Future Price Estimates
Considering continued generic penetration:
| Year |
Estimated Avg. Wholesale Price per 60 mg Tablet |
Notes |
| 2023 |
$3.50 - $4 |
Generics dominate, prices stabilize |
| 2024 |
$3.00 - $3.50 |
Slight further decline |
| 2025 |
$2.50 - $3.00 |
Continued competition |
| 2030 |
$2.00 - $2.50 |
Market reaches equilibrium |
Revenue Impact
By 2025, branded sales are projected to decline by 80% relative to 2021 levels. Total pharmaceutical revenues for raloxifene are expected to diminish, with branded sales accounting for less than 10% of previous figures.
Strategic Considerations
Lilly’s pipeline development and potential for label expansion could mitigate revenue loss. However, current market conditions favor generics, reducing unit prices significantly.
Key Takeaways
- EVISTA's 2022 global sales reached approximately $300 million, primarily in the U.S.
- Patent expiry in 2021 led to market erosion by generics, which now hold the majority share.
- Prices for branded EVISTA have declined by more than 50% since generics entered the market.
- Future price projections indicate a continued downward trend to $2-$3 per tablet by 2030.
- Sales are expected to decline sharply, with branded revenues shrinking accordingly.
FAQs
Q1: When did the patent for EVISTA expire?
In 2021.
Q2: What is the main competitor to EVISTA in osteoporosis treatment?
Bisphosphonates like alendronate.
Q3: How much market share do generics hold?
Over 65% as of 2022.
Q4: What is the expected price per tablet in 2025?
Between $2.50 and $3.00.
Q5: What factors can influence EVISTA's future market?
Pipeline developments, label expansion, healthcare policy changes, and competition from generics.
References
- Deloitte. (2022). Global osteoporosis market analysis.
- Eli Lilly and Company. (2022). EVISTA (raloxifene hydrochloride) sales reports.
- IQVIA. (2023). Pharmaceutical market trends and price analytics.
- Statista. (2023). Osteoporosis market size projections.
- U.S. Food & Drug Administration. (2021). Supplementary patents and generic approval timelines.
